Daunorubicin is an anthracycline antineoplastic agent that inhibits DNA and RNA synthesis. It is used in treatment protocols for acute lymphoblastic leukaemia, acute myelogenous leukaemia and acute promyelocytic leukaemia.

### INN
Daunorubicin

### ATC codes
L01DB02

### Medicine type
Chemical agent

### EML status history
- First added in 1999 (TRS 895) for **Lymphoid leukaemia, not elsewhere classified**
- Added in 1999 (TRS 895) for **Acute myeloid leukaemia with recurrent genetic abnormalities**
- Added in 1999 (TRS 895) for **Myeloid leukaemia**

### Indications
- **Lymphoid leukaemia, not elsewhere classified**
- **Myeloid leukaemia**
- **Acute myeloid leukaemia with recurrent genetic abnormalities**

### Recommendations

**Section**

**Cytotoxic medicines**

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)